BioVie Completes $10.4 Million Public Offering

BioVie ( (BIVI) ) has issued an update.

On August 7, 2025, BioVie Inc. entered into an underwriting agreement with ThinkEquity LLC for a public offering of 5,620,000 units and 380,000 pre-funded units, raising approximately $10.4 million after expenses. The offering closed on August 11, 2025, with the proceeds intended for working capital and general corporate purposes. The units, consisting of common stock and warrants, began trading on Nasdaq under the symbol ‘BIVIW’ on August 8, 2025. This move is expected to strengthen BioVie’s financial position and support its ongoing drug development efforts.

The most recent analyst rating on (BIVI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on BioVie stock, see the BIVI Stock Forecast page.

Spark’s Take on BIVI Stock

According to Spark, TipRanks’ AI Analyst, BIVI is a Underperform.

BioVie faces significant financial challenges as it remains in the R&D phase with no revenue. The strong equity position offers some balance sheet support, but high cash burn and reliance on external financing are concerns. Technical indicators show bearish momentum, and valuation metrics reflect typical pre-revenue biotech risks. Overall, the stock is rated poorly due to these combined factors.

To see Spark’s full report on BIVI stock, click here.

More about BioVie

BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders such as Alzheimer’s and Parkinson’s diseases, as well as Long COVID and advanced liver disease. The company is working on drug candidates like bezisterim for neurodegenerative diseases and BIV201 for liver disease, with the latter having FDA Fast Track status.

Average Trading Volume: 118,411

Technical Sentiment Signal: Strong Sell

Current Market Cap: $3.11M

See more data about BIVI stock on TipRanks’ Stock Analysis page.